Adherium’s Smartinhaler platform will be used in a new US clinical study that aims to improve medication adherence in patients with COPD by AstraZeneca.

The study will be conducted at seven US healthcare centres, and enrol nearly 400 COPD patients, starting in August. The study will end after 12 months.

The SmartTouch Symbicort device that will be used in this study features a modernized industrial design, miniaturization of electronic sensors, and improved usability, each showcasing the investment Adherium has made in its technology since listing on the ASX in August 2015.

Get the full story at